Vertex Pharmaceuticals Inc (VRTX)vsExicure Inc (XCUR)
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
XCUR
Exicure Inc
$4.61
+3.13%
HEALTHCARE · Cap: $28.49M
Smart Verdict
WallStSmart Research — data-driven comparison
VRTX leads profitability with a 32.9% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 66/100 (B-).
VRTX
Strong Buy66
out of 100
Grade: B-
XCUR
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Intrinsic value data unavailable for XCUR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bull Case : XCUR
XCUR has a balanced fundamental profile.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Bear Case : XCUR
The primary concerns for XCUR are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
VRTX profiles as a mature stock while XCUR is a value play — different risk/reward profiles.
XCUR carries more volatility with a beta of 4.19 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 26/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Exicure Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Exicure, Inc., a clinical-stage biotechnology company, develops therapies for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. The company is headquartered in Chicago, Illinois.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?